Orthocell Limited


Orthocell Limited ASX:OCCOrthocell Limited (ASX:OCC) is a commercial-stage, regenerative medicine company focused on developing products for a variety of tendon, cartilage and soft tissue injuries. Orthocell's portfolio of products include TGA-approved stem cell therapies Autologous Tenocyte Implantation (Ortho-ATI*TM) and Autologous Chondrocyte Implantation (Ortho-ACI*TM), which aim to regenerate damaged tendon and cartilage tissue. The Company's other major product is Celgro*TM, a collagen medical device which facilitates tissue repair and healing in a variety of orthopaedic, reconstructive and surgical applications and is being readied for first regulatory approvals.


View in Other Languages


Chapmans Limited (ASX:CHP) to Make Strategic Medicinal Cannabis Sector Investment

🕔8/29/2017 12:35:47 PM 8504

The Directors of Chapmans Limited (ASX:CHP) are pleased to announce that the Company has entered into a Binding Heads of Agreement with MJ Life Sciences Pty Ltd, to make a strategic investment of US$500,000 in MJLS.

Read Full Article

Orthocell Limited (ASX:OCC) First Human Tendons Grown In Laboratory

🕔11/6/2014 11:41:32 AM 7189

Regenerative medicine company Orthocell Limited (ASX:OCC) announced today its success in growing human tendons in a laboratory for the first time.

Read Full Article


  • This Page Viewed: (Last 7 Days: 7) (Last 30 Days: 29) (Since Published: 4704) 

Company Data

    Principal Sector
  • Health & Pharm 
  • Principal Industry
  • Biotechnology 
  • Homepage
  • www.orthocell.com